{"id":208404,"name":"NIGHTHAWK BIOSCIENCES, INC.","slug":"nighthawk-biosciences-inc","state":"NC","country":"United States of America","description":"biopharmaceutical company","totalSpending":620000,"filings":12,"yearlySpending":[{"year":2021,"income":220000},{"year":2022,"income":240000},{"year":2023,"income":160000}],"issues":[{"code":"HCR","display":"Health Issues"},{"code":"DEF","display":"Defense"}],"firms":["CROSSROADS STRATEGIES, LLC"],"lobbyists":["TODD WEISS","MATHEW LAPINSKI","MARC NUMEDAHL","JASON VAN PELT","SAMUEL ADCOCK","JASON GLEASON","BRITTANY HERNANDEZ"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["Legislative and regulatory issues impacting the development of therapies to modulate the immune system, including COVID-19 and other vaccine programs.","Legislative and regulatory issues impacting the development of therapies to modulate the immune system, including COVID-19 and other vaccine programs.","Issues impacting the development of medical countermeasures.","Legislative and regulatory issues impacting the development of therapies to modulate the immune system, including COVID-19 and other vaccine programs.","Issues impacting the development of medical countermeasures."]}